The medication will be produced at the company’s 23,000 square meter manufacturing site in Kwazulu-Natal
Cipla Medpro, the South African subsidiary of the Indian firm, has bagged the order as part of the South African government’s 2015-17 National ARV tender. The medication will be produced at the company’s 23,000 square meter manufacturing site in Kwazulu-Natal. According to a report in PTI, the contract is effective from 1 April, 2015 and will run for a period of three years, Cipla said in a filing to the BSE.
“We are proud to have won this tender which is not only testament to our high quality product portfolio, but is also in line with Cipla’s ethos of advancing healthcare for all South Africans,” said Subhanu Saxena, Managing Director and Global Chief Executive Officer, Cipla.
Commenting on the development, Paul Miller, Chief Executive Officer, Cipla Medpro said Cipla is known as a pioneer of fixed dose combinations, following Yusuf Hamied’s accomplishment of making AIDS medication available for a dollar a day in 2001.
“We intend to continue this proud tradition and build on the foundation laid to continue our quest of providing affordable healthcare to all,” Miller added.